CEFEPIME HYDROCHLORIDE · QILU ANTIBIOTICS
Cefepime hydrochloride is a fourth-generation cephalosporin antibiotic indicated for the treatment of moderate to severe pneumonia, empiric therapy for febrile neutropenic patients, and both uncomplicated and complicated urinary tract infections (including pyelonephritis). It is also used to treat uncomplicated skin and skin structure infections. For the treatment of complicated intra-abdominal infections in adults, it must be used in combination with metronidazole.
How CEFEPIME HYDROCHLORIDE Works
Cefepime is a bactericidal agent that acts by inhibiting bacterial cell wall synthesis. It exerts its effect by binding to one or more penicillin-binding proteins (PBPs), which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, ultimately leading to cell lysis.
Details
- Status
- Prescription
- First Approved
- 1996-01-18
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CEFEPIME HYDROCHLORIDE Approval History
What CEFEPIME HYDROCHLORIDE Treats
6 indicationsCEFEPIME HYDROCHLORIDE is approved for 6 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.
CEFEPIME HYDROCHLORIDE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CEFEPIME HYDROCHLORIDE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT01484015 | IRB00015247 NCI-2011-02422, CCCWFU 02110 | Ph 1 | completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFEPIME HYDROCHLORIDE FDA Label Details
Indications & Usage
Cefepime for injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. Empiric therapy for febrile neutropenic patients. Uncomplicated and complicated urinary tract infections (including pyelonephritis). Uncomplicated skin and skin structure infections. Complicated intra-abdominal infections (used in combination with metronidazole) in adults. 1.1 Pneumonia Cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Strep...
Looking for the branded version?
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
Full clinical data, patents, trials, and competitive landscape for cefepime hydrochloride.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.